ClinicalTrials.gg
CompletedNCT01622569Updated Dec 26, 2018Results posted

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

A Phase 3 interventional study of Fluticasone Propionate in Bilateral Nasal Polyposis, sponsored by Optinose US Inc.. Completed at 33 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.

Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral nasal polyposis. Two co-primary endpoints will be used in the study: reduction of nasal congestion/obstruction symptoms at the end of Week 4 of the double-blind treatment phase measured by the 7 day average instantaneous AM diary symptom scores, and reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by the Lildholdt scale score measured by nasoendoscopy.

Read the detailed description

This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study designed to assess the efficacy and safety of intranasal administration of 3 doses of OPN-375 (100, 200, and 400 µg bid) in subjects with bilateral nasal polyposis and nasal congestion.

This study consisted of 3 phases. After signing informed consent, subjects who met eligibility criteria at Visit 1 (screening) entered the study.

  1. Pretreatment phase (single-blind, placebo, run-in): 7 to up to 14 days duration, to determine disease status eligibility and to ensure the subject was able to comply with study procedures prior to randomization and enrolment in the double-blind treatment phase.
  2. Double-blind treatment phase: 16 weeks duration with 6 scheduled visits starting with Visit 2, Day 1 (baseline) when eligible subjects were randomized by balance allocation to 1 of 4 treatment groups and ending at Visit 7 (Week 16).
  3. Open-label extension phase: 8 weeks duration with 1 scheduled visit (Visit 8 [Week 24]).
02

Conditions studied

  • Bilateral Nasal Polyposis
03

In context

Lead sponsor

Optinose US Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 years and older
  • Women must

    • be practicing an effective method of (eg,prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    • be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal ligation at least 1 year before screening) or otherwise be incapable of pregnancy, or
    • be (spontaneous amenorrhea for at least 1 year).
  • Women of must have a negative serum beta-human chorionic gonadotropin (B-hCG) or urine pregnancy test (depending on local regulations) at the screening visit
  • Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by the Lildholdt scale score measured by nasoendoscopy at both screening and baseline visits
  • Must have at least moderate symptoms of nasal congestion/obstruction as reported by the subject for the 7 day period preceding the screening visit
  • At the baseline visit (Day 1), must have a morning score of at least 2 (moderate) on nasal congestion/obstruction recorded on the subject diary for at least 5 of the last 7 days of the 7 to up to 14 day run-in period
  • Must demonstrate an ability to correctly complete the daily diary during the run-in period to be eligible for randomization
  • Subjects with comorbid asthma or must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral use) within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at least 3 months before screening with plans to continue use throughout the study.
  • Must be able to cease treatment with intranasal medications including, but not limited to, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, inhaled corticosteroids (except permitted doses listed above for comorbid asthma and COPD) at the screening visit
  • Must be able to cease treatment with oral and nasal decongestants and antihistamines at the screening visit
  • Must be able to use the OptiNose device correctly; all subjects will be required to demonstrate correct use of the placebo device at screening, Visit 1.
  • Must be capable, in the opinion of the investigator, of providing to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Have complete or near-complete obstruction of the nasal cavities
  • Inability to achieve bilateral nasal airflow for any reason including nasal septum deviation
  • Inability to have each nasal cavity examined for any reason including nasal septum deviation
  • Nasal septum perforation
  • Has had more than 1 episode of epistaxis with frank bleeding in the month before the screening visit
  • Have evidence of significant baseline mucosal injury, ulceration or erosion (eg, exposed cartilage, perforation) on baseline nasal examination/nasal endoscopy
  • History of more than 5 sinonasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime)
  • History of sinus or nasal surgery within 6 months before the screening visit
  • History of any surgical procedure that prevents the ability to accurately grade polyps
  • Have symptoms of seasonal allergic rhinitis at screening or baseline and/or, based on time of year, would anticipate onset of symptoms within 4 weeks of randomization
  • Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  • Have significant oral structural abnormalities, eg, a cleft palate
  • Diagnosis of cystic fibrosis
  • History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  • Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution Note: Subjects who are taking prophylactic antibiotics will be allowed to enter the study as long as they intend to continue the antibiotics for the duration of the study.
  • Planned sinonasal surgery during the period of the study
  • Allergy, , or to or steroids
  • Allergy or hypersensitivity to any in study drug
  • Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before the screening visit; except as noted in inclusion criteria for subjects with comorbid asthma or
  • Have nasal candidiasis
  • Have taken a potent inhibitor within 14 days before the screening visit.
  • History or current diagnosis of any form of glaucoma or ocular hypertension (ie, >21 mmHg)
  • History of intraocular pressure elevation on any form of steroid therapy
  • History or current diagnosis of the presence (in either eye) of a cataract
  • Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
  • A recent (within 1 year of the screening visit) history of drug or alcohol use, abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
  • Positive urine drug screen at screening visit for drugs of abuse, with the exception of prescribed medications for legitimate medical conditions
  • Have participated in an drug clinical trial within 30 days of the screening visit
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
323 participants (actual)

Study arms

  • Active comparator
    OPN-375 100 μg BID

    Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks

    Drug: Fluticasone Propionate

  • Placebo comparator
    Placebo

    Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks

    Drug: Fluticasone Propionate

  • Active comparator
    OPN-375 200 μg BID

    Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks

    Drug: Fluticasone Propionate

  • Active comparator
    OPN-375 400 μg BID

    Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks

    Drug: Fluticasone Propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms

    Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase

    Time frame: Baseline, Week 4 of the double-blind treatment phase

  2. Change in Total Polyp Grade

    Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline

    Time frame: Baseline, Week 16 of the double-blind treatment phase

Secondary outcomes

  1. Congestion/Obstruction Scores (7-day Instantaneous Morning)

    Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

    Time frame: Baseline, Week 16 of the double-blind treatment phase

  2. Change in Rhinorrhea Score (7-day Instantaneous Morning)

    Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

    Time frame: Baseline, Week 16 of the double-blind treatment phase

  3. Facial Pain or Pressure Score (7-day Instantaneous Morning)

    Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

    Time frame: Baseline, Week 16 of the double-blind treatment phase

  4. Hyposmia Score (7-day Instantaneous Morning)

    Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

    Time frame: Baseline, Week 16 of the double-blind treatment phase

  5. Sinonasal Outcome Test 22 (SNOT-22) Total Score

    SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be

    Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase

  6. MOS Sleep-R Score

    The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.

    Time frame: Baseline, Week 16 of the double-blind treatment phase

  7. Rhinosinusitis Disability Index (RSDI) Total Score

    The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.

    Time frame: Baseline, Week 16 of the double-blind treatment phase

  8. SF-36v2 - Mental Component

    The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.

    Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase

  9. SF-36v2 - Physical Component

    The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.

    Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase

  10. Patient Global Impression of Change (PGIC) Score

    Subject responses to the question: "Since starting the study drug, how would you rate the change in your symptoms?" Percentage includes patients who scored either "very much improved," "much improved," or "minimally improved."

    Time frame: Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase

  11. Peak Nasal Inspiratory Flow (PNIF)

    The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.

    Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label treatment phase

  12. Polyp Grade of 0 in at Least One Nostril

    Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

    Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase

  13. Nasal Polyp Surgery Eligilbilty

    A subject was considered eligible for surgical intervention if the following conditions were met: * Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months. * Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks. * Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks. * Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).

    Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase

07

Results

Posted Dec 5, 2018

Participant flow

Double-Blind Treatment Phase (Wks 1-16)
Participant flow — Double-Blind Treatment Phase (Wks 1-16)
MilestonePlacebo100 μg OPN-375200 μg OPN-375400 μg EDS-FLU
Started82818080
Completed70757176
Not completed12694
Withdrew: Adverse event4231
Withdrew: Lost to follow-up0010
Withdrew: Lack of efficacy6032
Withdrew: Protocol violation0201
Withdrew: Withdrawal by subject2220
Open-Label Extension Phase (Wks 17-24)
Participant flow — Open-Label Extension Phase (Wks 17-24)
MilestonePlacebo100 μg OPN-375200 μg OPN-375400 μg EDS-FLU
Started68726775
Completed67706473
Not completed1232
Withdrew: Adverse event0210
Withdrew: Lack of efficacy1021
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryChange in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms

Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase

Time frame:
Baseline, Week 4 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms-0.26 ± 0.08-0.53 ± 0.08-0.56 ± 0.08-0.67 ± 0.08
PrimaryChange in Total Polyp Grade

Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline

Time frame:
Baseline, Week 16 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
Change in Total Polyp Grade
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Change in Total Polyp Grade-0.57 ± 0.14-1.04 ± 0.14-1.14 ± 0.14-1.14 ± 0.14
SecondaryCongestion/Obstruction Scores (7-day Instantaneous Morning)

Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

Time frame:
Baseline, Week 16 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
Congestion/Obstruction Scores (7-day Instantaneous Morning)
units on a scalePlaceboOPN-375 100 μg Twice DailyOPN-375 200 μg Twice DailyOPN-375 400 μg Twice Daily
Congestion/Obstruction Scores (7-day Instantaneous Morning)-0.53 ± 0.11-0.93 ± 0.10-0.99 ± 0.10-1.07 ± 0.10
SecondaryChange in Rhinorrhea Score (7-day Instantaneous Morning)

Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

Time frame:
Baseline, Week 16 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
Change in Rhinorrhea Score (7-day Instantaneous Morning)
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Change in Rhinorrhea Score (7-day Instantaneous Morning)-0.50 ± 0.10-0.80 ± 0.10-0.89 ± 0.10-0.92 ± 0.10
SecondaryFacial Pain or Pressure Score (7-day Instantaneous Morning)

Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

Time frame:
Baseline, Week 16 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
Facial Pain or Pressure Score (7-day Instantaneous Morning)
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Facial Pain or Pressure Score (7-day Instantaneous Morning)-0.41 ± 0.11-0.65 ± 0.10-0.72 ± 0.10-0.68 ± 0.10
SecondaryHyposmia Score (7-day Instantaneous Morning)

Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase

Time frame:
Baseline, Week 16 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
Hyposmia Score (7-day Instantaneous Morning)
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Hyposmia Score (7-day Instantaneous Morning)-0.23 ± 0.12-0.45 ± 0.11-0.53 ± 0.11-0.60 ± 0.11
SecondarySinonasal Outcome Test 22 (SNOT-22) Total Score

SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be

Time frame:
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Reported as:
Least squares mean · units on a scale
Sinonasal Outcome Test 22 (SNOT-22) Total Score
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Change from baseline to Week 16-10.96 ± 2.07-18.32 ± 2.05-19.56 ± 2.04-19.80 ± 2.05
Change from baseline to Week 24 (all pts on 400 μg-20.78 ± 2.10-21.20 ± 2.07-23.28 ± 2.08-21.72 ± 2.07
SecondaryMOS Sleep-R Score

The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.

Time frame:
Baseline, Week 16 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
MOS Sleep-R Score
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
MOS Sleep-R Score-8.53 ± 1.61-10.96 ± 1.59-14.24 ± 1.59-10.66 ± 1.55
SecondaryRhinosinusitis Disability Index (RSDI) Total Score

The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.

Time frame:
Baseline, Week 16 of the double-blind treatment phase
Reported as:
Least squares mean · units on a scale
Rhinosinusitis Disability Index (RSDI) Total Score
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Rhinosinusitis Disability Index (RSDI) Total Score-10.71 ± 2.07-17.08 ± 1.99-16.44 ± 2.02-16.37 ± 1.94
SecondarySF-36v2 - Mental Component

The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.

Time frame:
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Reported as:
Least squares mean · units on a scale
SF-36v2 - Mental Component
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Week 160.70 ± 0.873.19 ± 0.844.03 ± 0.851.83 ± 0.82
Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)4.44 ± 0.833.37 ± 0.805.82 ± 0.843.61 ± 0.78
SecondarySF-36v2 - Physical Component

The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.

Time frame:
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Reported as:
Least squares mean · units on a scale
SF-36v2 - Physical Component
units on a scalePlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Week 162.67 ± 0.764.12 ± 0.745.19 ± 0.743.58 ± 0.72
Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)6.97 ± 0.786.55 ± 0.757.18 ± 0.784.90 ± 0.73
SecondaryPatient Global Impression of Change (PGIC) Score

Subject responses to the question: "Since starting the study drug, how would you rate the change in your symptoms?" Percentage includes patients who scored either "very much improved," "much improved," or "minimally improved."

Time frame:
Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) Score
ParticipantsPlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Week 1651566267
Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)59626266
SecondaryPeak Nasal Inspiratory Flow (PNIF)

The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.

Time frame:
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label treatment phase
Reported as:
Least squares mean · L/min
Peak Nasal Inspiratory Flow (PNIF)
L/minPlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BID
Week 1617.26 ± 6.1536.57 ± 6.0635.94 ± 6.0835.43 ± 5.95
Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)34.92 ± 6.3141.61 ± 6.2144.70 ± 6.2735.64 ± 6.09
SecondaryPolyp Grade of 0 in at Least One Nostril

Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

Time frame:
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Reported as:
Count of participants · Participants
Polyp Grade of 0 in at Least One Nostril
ParticipantsPlaceboOPN-375 100 μg Twice DailyOPN-375 200 μg Twice DailyOPN-375 400 μg Twice Daily
Week 169191214
Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)17241619
SecondaryNasal Polyp Surgery Eligilbilty

A subject was considered eligible for surgical intervention if the following conditions were met: * Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months. * Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks. * Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks. * Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).

Time frame:
Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase
Reported as:
Count of participants · Participants
Nasal Polyp Surgery Eligilbilty
ParticipantsPlacebo100 μg OPN-375200 μg OPN-375400 μg EDS-FLU
Week 1627172119
Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)15141716

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double-Blind Phase)0/82 (0%)0/82 (0%)42/82 (51.2%)
OPN-375 100 μg BID (Double-Blind Phase)0/81 (0%)1/81 (1.2%)40/81 (49.4%)
OPN-375 200 μg BID (Double-Blind Phase)0/80 (0%)0/80 (0%)45/80 (56.3%)
OPN-375 400 μg BID (Double-Blind Phase)0/79 (0%)1/79 (1.3%)50/79 (63.3%)
OPN-375 400 μg (Open-Label Phase)0/282 (0%)2/282 (0.7%)38/282 (13.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Double-Blind Phase)OPN-375 100 μg BID (Double-Blind Phase)OPN-375 200 μg BID (Double-Blind Phase)OPN-375 400 μg BID (Double-Blind Phase)OPN-375 400 μg (Open-Label Phase)
MenorrhagiaReproductive system and breast disorders0/820/810/801/790/282
Nasal PolypsRespiratory, thoracic and mediastinal disorders0/821/810/800/791/282
PneumoniaInfections and infestations0/820/810/800/791/282
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo (Double-Blind Phase)OPN-375 100 μg BID (Double-Blind Phase)OPN-375 200 μg BID (Double-Blind Phase)OPN-375 400 μg BID (Double-Blind Phase)OPN-375 400 μg (Open-Label Phase)
Epistaxis (Found on Nasoendoscopy)Respiratory, thoracic and mediastinal disorders3/828/819/8013/794/282
Nasal Mucosal DisorderRespiratory, thoracic and mediastinal disorders5/8211/816/806/791/282
Acute SinusitisInfections and infestations4/825/816/808/793/282
Epistaxis (Spontaneously Reported by Subject)Respiratory, thoracic and mediastinal disorders3/823/817/806/7912/282
Upper Respiratory Tract InfectionInfections and infestations7/821/814/805/792/282
Nasal CongestionRespiratory, thoracic and mediastinal disorders4/823/812/806/791/282
Nasal Septal UlcerationRespiratory, thoracic and mediastinal disorders1/825/815/804/795/282
AsthmaRespiratory, thoracic and mediastinal disorders5/820/811/803/791/282
NasopharyngitisInfections and infestations4/823/812/804/793/282
BronchitisInfections and infestations2/822/812/803/790/282

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
Mean45.3 ± 13.044.9 ± 12.746.4 ± 12.743.9 ± 12.645.1 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
Female46413242161
Male36404838162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
White68747269283
Black/African American836926
Asian52209
Other12025
Region of Enrollment
Region of Enrollment(Participants)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
Canada455418
Czechia1415141356
United Kingdom322411
Ukraine1617161665
United States36363536143
South Africa968730
Total Polyp Grading Score (sum of scores from both nasal cavities)
Total Polyp Grading Score (sum of scores from both nasal cavities)(Units on a Scale)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
Mean3.8 (2 to 6)3.6 (2 to 6)3.9 (2 to 6)3.7 (2 to 6)3.75 (2 to 6)
Use of intranasal corticosteroid (ICS) treatment for polyps in past 10 years
Use of intranasal corticosteroid (ICS) treatment for polyps in past 10 years(Participants)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
Count of participants77777675305
Previous sinus surgery for polyp removal or sinus surgery
Previous sinus surgery for polyp removal or sinus surgery(Participants)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
Count of participants33342730124
Previous polyp removal surgery via polypectomy only
Previous polyp removal surgery via polypectomy only(Participants)PlaceboOPN-375 100 μg BIDOPN-375 200 μg BIDOPN-375 400 μg BIDTotal
Count of participants33273327120

11 further baseline measures are reported on the registry.

08

Study locations

33 sites
  • SC Clinical Research, Inc.
    Tucson, Arizona 85704, United States
  • Kern Allergy and Medical Research, Inc.
    Bakersfield, California 93301, United States
  • Central California Clinical Research
    Fresno, California 93720, United States
  • Allergy & Asthma Specialists Medical Group
    Huntington Beach, California 92647, United States
  • California Allergy & Asthma Medical Group, Inc.
    Los Angeles, California 90025, United States
  • Choc PSF, AMC, Division of AA & I
    Orange, California 92868, United States
  • California Allergy and Asthma Palmdale
    Palmdale, California 93551, United States
  • Peninsula Research Associates, Inc.
    Rolling Hills Estates, California 90274, United States
  • California Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • Asthma & Allergy Associates, P.C.
    Colorado Springs, Colorado 80907, United States
  • Colorado ENT & Allergy
    Colorado Springs, Colorado 80909, United States
  • Colorado Allergy and Asthma Centers, P.C.
    Denver, Colorado 80230, United States
  • University of South Florida Asthma, Allergy & Immunology
    Tampa, Florida 33613, United States
  • NU Feinberg School of Medicine Depart. of Otolaryngology-Head & Neck Surgery
    Chicago, Illinois 60611, United States
  • Chicago ENT
    Chicago, Illinois 60657, United States
  • Northeast Medical Research Associates, Inc
    North Dartmouth, Massachusetts 02747, United States
  • The Center for Pharmaceutical Research, P.C.
    Kansas City, Missouri 64114, United States
  • Clinical Research Group of Montana, PLLC
    Bozeman, Montana 59718, United States
  • Coastal Ear, Nose and Throat, LLC
    Neptune, New Jersey 07753, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Optimed Research
    Columbus, Ohio 43235, United States
  • Allergy, Asthma & Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Vital Prospects Clinical Research Institute
    Tulsa, Oklahoma 74136, United States
  • National Allergy, Asthma & Urticaria Centers of Charleston, P.A.
    North Charleston, South Carolina 29420, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Ear Nose and Throat Associates of Texas
    Frisco, Texas 43235, United States
  • ENTTEX
    Plano, Texas 75093, United States
  • EVMS Depart. Of Otolaryngology
    Norfolk, Virginia 23507, United States
  • Allergy, Asthma & Sinus Center, S.C.
    Greenfield, Wisconsin 53228, United States
  • Ottawa Allergy Research Corporation
    Ottawa, Ontario K1Y 4G2, Canada
  • CHUM Hôtel-Dieu
    Montreal, Quebec H2W 1T8, Canada
  • Dr. Jaime Del Carpio
    Montreal, Quebec H3G 1L5, Canada
09

References and documents

Publications

  • Ow RA, McGinnis JP 2nd, Sacks HJ, Mehle ME. The Effect of EDS-FLU on Objective and Patient-Reported Subjective Outcomes for Patients with Chronic Rhinosinusitis with Nasal Polyps. Ear Nose Throat J. 2025 Feb;104(2):93-101. doi: 10.1177/01455613221088698. Epub 2022 Apr 18. PubMed 35437059 ↗
  • Skoner DP, Meltzer EO, Skoner J, Sacks HJ, Lumry WR. Evaluation of the ocular safety associated with the exhalation delivery system with fluticasone. Allergy Asthma Proc. 2022 Jan 9;43(1):70-77. doi: 10.2500/aap.2022.43.210096. Epub 2021 Nov 9. PubMed 34753535 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in Aug 2015, 20 months.

Results were first posted in Dec 2018, 3 years 3 months after primary completion. A results delay was requested in Jul 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2012
First posted
Jun 19, 2012
StartActual
Nov 19, 2013
Primary completionActual
Aug 6, 2015
CompletionActual
Oct 1, 2015
Results delay requested
Jul 25, 2016
Results first posted
Dec 5, 2018
Last update
Dec 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01622569
Lead sponsor
Optinose US Inc.
Responsible party
Sponsor
First posted
Jun 19, 2012
Start date
Nov 19, 2013
Primary completion
Aug 6, 2015
Completion
Oct 1, 2015
Results posted
Dec 5, 2018
Last update
Dec 26, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion